(Q35186892)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

title

Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

Beran M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

DiPersio J

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Slack J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Vey N

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Rosenfeld CS

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Greenberg P

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 August 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

1499-1507

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12886236%20AND%20SRC:MED&resulttype=core&format=json

Establishing the incidence of myelodysplastic syndrome

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Arsenic trioxide: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Future directions with platelet growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Pilot study of low-dose interleukin-11 in patients with bone marrow failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

All-trans retinoic acid in the treatment of myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

New approaches to the treatment of myelodysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Arsenic trioxide in multiple myeloma: rationale and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all- trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

Antithymocyte globulin for patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021

Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403021

7 January 2021